Key Highlights

  • Adherium Ltd (ASX:ADR) was trading at A$0.06, down 14.29%, during the 23 October 2026 trading session.
  • In its Appendix 4E for the year ended 30 June 2026, the company reported Revenue of $2,100,479, up 157%, and a loss after tax of $14,161,734.
  • The S&P/ASX 200 was down 0.37% at 1:16 pm AEDT on 23 October 2026.

Adherium Ltd (ASX:ADR) was trading at A$0.06, down 14.29%, during the 23 October 2026 trading session, a much larger decline than the S&P/ASX 200 (XJO), which was at 8,760.50, down 0.37% (down 32.70 points) at 1:16 pm AEDT. Adherium provides remote patient monitoring, including adherence and technique monitoring, to customers for a monthly subscription fee, and its filing describes a transition from a Clinical Trials company to a data-driven remote patient monitoring company. The company's latest financial update is its Appendix 4E preliminary financial statements for the year ended 30 June 2026, which reported revenue of $2,100,479 and a loss after tax of $14,161,734. The text reviewed does not show a lodgement date for the document, and it is not dated 23 October 2026, so no link to today's move is made.

Latest Developments

Results for the year ended 30 June 2026 (Appendix 4E)

In its Appendix 4E for the 12 months ended 30 June 2026, Adherium reported revenue from ordinary activities of $2,100,479, compared with $817,237 in the previous corresponding period, an increase of 157%. The loss from ordinary activities after tax attributable to members was $14,161,734, compared with $12,679,349, a 12% increase in the loss. Net Tangible Asset backing was 0.02 cents per ordinary share, compared with 0.9 cents a year earlier.

The company said revenue rose as it launched its remote patient monitoring program in the United States. It also said revenue growth was moderated by the timing of patient onboarding as the monitoring program was refined to meet the needs of customers and their patients, and that month-on-month growth in remote patient monitoring subscription revenue was achieved during FY26.

Cost movements and cash position

Adherium said the loss reflected onboarding in the call centre and sales teams, an expanded engineering team and higher Payroll and contractor costs to enable commercial growth in the United States. According to the filing, Research and Development activities amounted to $2,080,937 (prior year: $3,441,139), which the company said reflected the shift from clinical trials and product development to commercialisation. Sales and Marketing costs were $1,804,218 (prior year: $4,290,344). Administrative expenses increased to $11,698,296 from $5,485,800, which the company attributed primarily to higher payroll and related on-costs, contractor and consulting costs, capital-raising costs and executive recruitment costs, and to the reclassification of certain employee costs. Cash at 30 June 2026 was $1,424,058, compared with $43,255 a year earlier.

Audit status and subsequent events

Adherium said the Appendix 4E is based on financial statements in the process of being audited, with audited statements to be published in September 2026. The company noted that, as in prior years, the independent auditor's report may contain an emphasis of matter reflecting a material uncertainty in respect of Going Concern relating to the raising of additional Capital or alternative funding until the group is supported by cash flows from operations. The directors said they consider that adoption of the going concern basis continues to be appropriate.

The filing also lists subsequent events: a $1 million Loan at 12% interest from Trudell accepted across July and August 2026, and a completed share consolidation at a 100:1 conversion.

About Adherium Ltd

Adherium Limited (ASX:ADR) provides remote patient monitoring technology. Its filing identifies a single operating segment based on the Hailie Smartinhaler product. The company states that it has moved from being a clinical trials company to a data-driven remote patient monitoring company that provides adherence and technique monitoring on a monthly subscription basis.

Related Sector Context

Adherium operates in digital health, specifically remote patient monitoring, a segment of the healthcare and technology sectors. Adherium's filing describes a move from product development to commercial programs, reflected in its cost lines, with lower research and development and sales and marketing costs alongside higher administrative expenses.

On 23 October 2026, the S&P/ASX 200 was down 0.37% at 1:16 pm AEDT, while Adherium was down 14.29% at A$0.06.

Risks to Weigh In

  • The company reported a loss after tax of $14,161,734 for FY26, up from $12,679,349 the year before.
  • The auditor's report may include an emphasis of matter on going concern relating to the raising of additional capital or alternative funding.
  • Cash at 30 June 2026 was $1,424,058, and the company has disclosed a $1 million loan at 12% interest accepted during July and August 2026.

Catalysts on Watch

  • Publication of the audited financial statements, which the company said would occur in September 2026.
  • Further growth in remote patient monitoring subscriptions in FY27, which the company said it is set up for.
  • Any additional capital raising or funding arrangements, which the company referred to in its going concern commentary.

Where Things Stand

Adherium traded lower during the 23 October 2026 trading session, down 14.29% at A$0.06, while the S&P/ASX 200 was down 0.37% at 1:16 pm AEDT. The company's most recent financial document, its Appendix 4E for the year ended 30 June 2026, sets out revenue of $2,100,479, a loss after tax of $14,161,734 and year-end cash of $1,424,058.